0.5245
0.0165 (3.25%)
0.0165 (3.25%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Canna Trader Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CV Sciences Inc (QB) | CVSI | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.0165 | 3.25% | 0.5245 | 15:58:50 |
| Close Price | Low Price | High Price | Open Price | Previous Close |
|---|---|---|---|---|
| 0.5245 | 0.5051 | 0.5245 | 0.5051 | 0.508 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 0.5105 | 0.5245 | 0.014 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 129 | 197,047 | $ 0.516277 | $ 101,731 | 361,115 | 0.25 - 2.39 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:58:50 | 5,000 | $ 0.5245 | USD |
CV Sciences (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 52.67M | 100.42M | 91.82M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 1.34M | $ - | 0.00% | - | - |
CV Sciences (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CVSI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.501 | 0.5357 | 0.50 | 0.5122133 | 169,977 | 0.0235 | 4.69% |
| 1 Month | 0.52505 | 0.83025 | 0.4725 | 0.5137411 | 222,820 | -0.00055 | -0.1% |
| 3 Months | 0.5751 | 0.89 | 0.44 | 0.5910231 | 368,039 | -0.0506 | -8.8% |
| 6 Months | 0.58 | 1.27 | 0.36 | 0.675721 | 634,768 | -0.0555 | -9.57% |
| 1 Year | 2.19 | 2.39 | 0.25 | 0.869841 | 764,764 | -1.67 | -76.05% |
| 3 Years | 0.24 | 9.20 | 0.136 | 2.97 | 1,239,255 | 0.2845 | 118.54% |
| 5 Years | 0.7601 | 9.20 | 0.10 | 2.38 | 968,865 | -0.2356 | -31.0% |
CV Sciences (QB) Description
| CV Sciences, Inc. operates two distinct business segments: a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors; and a pharmaceutical division focused on developing and commercializing CBD-based novel therapeutics. The Company's PlusCBD Oil consumer products are sold at more than 5,500 retail locations throughout the U.S. and it is the top-selling brand of hemp-derived CBD in the natural product retail market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences' state-of-the-art facility follows all guidelines for Good Manufacturing Practices (GMP) and the Company's hemp extracts are processed, produced, and tested throughout the manufacturing process to confirm purity and content to meet strict company quality standards. With a commitment to science, PlusCBD Oil's benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. PlusCBD Oil was the first hemp-derived CBD supplement brand to invest in the scientific evidence necessary to achieve self-affirmed Generally Recognized as Safe (GRAS) status. The Company's pharmaceutical division focuses on developing and commercializing proprietary prescription drugs utilizing cannabidiol (CBD) as the active pharmaceutical ingredient. CV Sciencesâ initial drug candidate (CVSI-007) combines CBD and nicotine, which the Company believes has the potential to effectively treat smokeless tobacco use and addiction. The market for cessation of smokeless tobacco use and addiction is estimated at greater than $2 billion. |
